Thrombotic risk factors in pulmonary hypertension

European Respiratory Journal

Volumn 15, Issue 2, 2000, Pages 395-399

  Wolf, M ^a   Boyer Neumann, C ^a   Parent, F ^b   Eschwege, V ^a   Jaillet, H ^b   Meyer, D ^a   Simonneau, G ^b  

^a Service d'Hematologie   (France)

^b Service de Pneumologie   (France)

Author keywords

Antiphospholipid antibodies; Lupus anticoagulant; Pulmonary hypertension; Thrombophilic factors

Indexed keywords

LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY;

ADULT; AGED; ARTICLE; FEMALE; GENETIC RISK; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RISK FACTOR; THROMBOEMBOLISM; THROMBOGENESIS;

ANTIBODIES, ANTIPHOSPHOLIPID; CASE-CONTROL STUDIES; CHRONIC DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYPERTENSION, PULMONARY; LUPUS COAGULATION INHIBITOR; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; THROMBOSIS;

EID: 0033951770     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3003.2000.15b28.x     Document Type: Article

References (27)

1. Rubin LJ. Primary pulmonary hypertension. Chest 1993; 104: 236-250.
2. Moser KM, Auger WR, Fedullo PF, Jamieson SW. Chronic thromboembolic pulmonary hypertension: clinical picture and surgical treatment. Eur Respir J 1992; 5: 334-342.
3. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
4. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′ untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and increase in venous thrombosis. Blood 1996; 88: 3698-3703.
5. Moser KM, Auger WR, Fedullo PF. Chronic major-vessel thromboembolic pulmonary hypertension. Circulation 1990; 81: 1735-1743.
6. Lang IM, Klepetko W, Pabinger I. No increased prevalence of the factor V Leiden mutation in chronic major vessel thromboembolic pulmonary hypertension (CTEPH). Thromb Haemost 1996; 76: 476-477.
7. Butt AY, Cremona G, Wood G, Katayama Y, Higenbottam TW. Anticardiolipin antibodies and pulmonary hypertension. Am Rev Respir Dis 1996; A726.
8. Auger WR, Permpikul P, Moser KM. Lupus anticoagulant, heparin use, and thrombocytopenia in patients with chronic thromboembolic pulmonary hypertension: a preliminary report. Am J Med 1995; 99: 392-396.
9. Greaves M. Antiphospholipid antibodies and thrombosis. Lancet 1999; 353: 1348-1353.
10. Schulman S, Svenungsson E, Granquist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med 1998; 104: 332-338.
11. Harris EN, Gharavi AE, Patel SP, Hughes GR. Evaluation of the anticardiolipin antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol 1987; 68: 215-222.
12. Rauch J, Tannenbaum M, Janoff A. Distinguishing plasma lupus anticoagulants from anti-factor antibodies using hexagonal II phase phospholipids. Thromb Haemost 1989; 62: 892-896.
13. Amiral J, Larrivaz I, Cluzeau D, Adam M. Standardization of immunoassays for antiphospholipid antibodies with beta 2GPI and role of other phospholipid cofactors. Haemostasis 1994; 24: 191-203.
14. Marfaing-Koka A, Boyer-Neumann C, Wolf M, Leroy-Matheron C, Cynober T, Tchnemia G. Decreased protein S activity in sickle cell disease. N Rev Fr Hemat 1993; 35: 425-430.
15. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215-1218.
16. Gandrille S, Athene Gelas M, Aiach M. A rapid screening method for the factor V Arg 506 - Gln mutation. Blood Coag Fibrinol 1995; 6: 245-248.
17. Kapiotis S, Speiser W, Pabinger-Fasching I, Kyrle PA, Lechner K. Anticardiolipin antibodies in patients with venous thrombosis. Haemostasis 1991; 21: 19-24.
18. Ginsberg JS, Wells PS, Brill-Edwards P, et al. Antiphospholipid antibodies and venous thromboembolism. Blood 1995; 86: 3685-3691.
19. Mateo J, Oliver A, Borrell M, Sala N, Fontcuberta J. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism. Results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). Thromb Haemost 1997; 77: 444-451.
20. Simioni P, Prandoni P, Zanon E, et al. Deep venous thrombosis and lupus anticoagulant. A case-control study. Thromb Haemost 1996; 76: 187-189.
21. Horbach DA, van Oort E, Donders RC, Derksen RH, de Groot PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost 1996; 76: 916-924.
22. Vila P, Hernandez MC, Lopez-Fernandez MF, Battle J. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemost 1994; 72: 209-213.
23. Finazzi G, Brancaccio V, Moia M, et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med 1996; 100: 530-536.
24. Levine SR, Salowich-Palm I, Sawoya KL, et al. IgG anticardiolipin antibody titer >40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study. Stroke 1997; 82: 1660-1665.
25. Rich S, Kieras K, Hart K, Groves BM, Stobo JD, Brundage BH. Antinuclear antibodies in primary pulmonary hypertension. J Am Coll Cardiol 1986; 8: 1307-1311.
26. Morse JH, Barst RJ, Fotino M, et al. Primary pulmonary hypertension, tissue plasminogen activator antibodies, and HLA-DQ7. Am J Respir Crit Care Med 1997; 155: 274-278.
27. Boyer-Neumann C, Brenot F, Wolf M, et al. Continuous infusion of prostacyclin decreases plasma levels of t-PA and PAI-1 in primary pulmonary hypertension. Thromb Haemost 1995; 73: 735-736.